Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 94.345
Filter
1.
Arch Virol ; 169(6): 132, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38822903

ABSTRACT

Orpheoviruses, cedratviruses, and pithoviruses are large DNA viruses that cluster together taxonomically within the order Pimascovirales of the phylum Nucleocytoviricota. However, they were not classified previously by the International Committee on Taxonomy of Viruses (ICTV). Here, we present a comprehensive analysis of the gene content, morphology, and phylogenomics of these viruses, providing data that underpinned the recent proposal to establish new taxa for their initial classification. The new taxonomy, which has now been ratified by the ICTV, includes the family Orpheoviridae and genus Alphaorpheovirus, the family Pithoviridae and genus Alphapithovirus, and the family Cedratviridae and genus Alphacedratvirus, aiming to formally catalogue the isolates covered in this study. Additionally, as per the newly adopted rules, we applied standardized binomial names for the virus species created to classify isolates with complete genome sequences available in public databases at the time of the proposal. The specific epithet of each virus species was chosen as a reference to the location where the exemplar virus was isolated.


Subject(s)
DNA Viruses , Genome, Viral , Phylogeny , Genome, Viral/genetics , DNA Viruses/genetics , DNA Viruses/classification , DNA, Viral/genetics
2.
J Med Virol ; 96(6): e29723, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38828911

ABSTRACT

Hepatitis B virus (HBV) can be completely suppressed after antiviral treatment; however, some patients with chronic hepatitis B (CHB) exhibit elevated alanine aminotransferase (ALT) levels and sustained disease progression. This study provides novel insights into the mechanism and potential predictive biomarkers of persistently elevated ALT (PeALT) in patients with CHB after complete viral inhibition. Patients having CHB with undetectable HBV DNA at least 12 months after antiviral treatment were enrolled from a prospective, observational cohort. Patients with PeALT and persistently normal ALT (PnALT) were matched 1:1 using propensity score matching. Correlations between plasma metabolites and the risk of elevated ALT were examined using multivariate logistic regression. A mouse model of carbon tetrachloride-induced liver injury was established to validate the effect of key differential metabolites on liver injury. Of the 1238 patients with CHB who achieved complete viral suppression, 40 (3.23%) had PeALT levels during follow-up (median follow-up: 2.42 years). Additionally, 40 patients with PnALT levels were matched as controls. Ser-Phe-Ala, Lys-Ala-Leu-Glu, 3-methylhippuric acid, 3-methylxanthine, and 7-methylxanthine were identified as critical differential metabolites between the two groups and independently associated with PeALT risk. Ser-Phe-Ala and Lys-Ala-Leu-Glu levels could be used to discriminate patients with PeALT from those with PnALT. Furthermore, N-acetyl- l-methionine (NALM) demonstrated the strongest negative correlation with ALT levels. NALM supplementation alleviated liver injury and hepatic necrosis induced by carbon tetrachloride in mice. Changes in circulating metabolites may contribute to PeALT levels in patients with CHB who have achieved complete viral suppression after antiviral treatment.


Subject(s)
Alanine Transaminase , Antiviral Agents , Biomarkers , Hepatitis B, Chronic , Humans , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/blood , Hepatitis B, Chronic/virology , Male , Female , Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Adult , Prospective Studies , Middle Aged , Biomarkers/blood , Animals , Mice , Hepatitis B virus , Sustained Virologic Response , DNA, Viral/blood , Disease Models, Animal , Liver/pathology , Liver/virology , Viral Load
3.
New Microbiol ; 47(1): 52-59, 2024 May.
Article in English | MEDLINE | ID: mdl-38700884

ABSTRACT

Monitoring Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infection after transplantation is recommended to enable preemptive therapy. However, the most suitable sample type remains unclear. Patients who underwent hematopoietic stem cell or liver transplantation were included in this study. Viral loads in sequential whole-blood and plasma samples were retrospectively analyzed. EBV DNA was detected more frequently in whole blood (55%) than in plasma (18%). The detection rate of CMV DNA was similar between the two sample types. The correlation of viral loads between the two sample types were 0.515 and 0.688 for EBV and CMV, respectively. Among paired samples in which EBV DNA was detected in whole blood, the plasma EBV detection rate was significantly higher in patients who underwent hematopoietic stem cell transplantation than in those who underwent liver transplantation. The viral DNA load in whole blood and plasma showed similar trends. The EBV detection rate was higher in whole blood, and a high correlation was observed between CMV DNA loads and whole blood and plasma. These results indicate that whole blood is more sensitive for monitoring both EBV and CMV, whereas plasma is a potential alternative sample for monitoring CMV.


Subject(s)
Cytomegalovirus Infections , Cytomegalovirus , Epstein-Barr Virus Infections , Herpesvirus 4, Human , Viral Load , Humans , Cytomegalovirus/genetics , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/virology , Cytomegalovirus Infections/blood , Cytomegalovirus Infections/diagnosis , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/isolation & purification , Epstein-Barr Virus Infections/virology , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Infections/diagnosis , Male , Female , Middle Aged , Adult , Retrospective Studies , DNA, Viral/blood , Young Adult , Hematopoietic Stem Cell Transplantation , Aged , Plasma/virology , Liver Transplantation , Adolescent
4.
PLoS One ; 19(5): e0302396, 2024.
Article in English | MEDLINE | ID: mdl-38696502

ABSTRACT

INTRODUCTION: The HIV/AIDS continues being a significant global public health priority in the 21st century with social and economic consequences Mother-to-child transmission (MTCT) occurs when an HIV-infected woman passes the virus to her infant and about 90% of these MTCT infections occurs in Africa where children and infants are still dying of HIV. Early definitive diagnosis using Deoxyribonucleic acid reaction of HIV infection in infants is critical to ensuring that HIV-infected infants receive appropriate and timely care and treatment to reduce HIV related morbidity and mortality. OBJECTIVE: To assess the Infant Deoxyribonucleic acid-Polymerase Chain Reaction (DNA-PCR) Turnaround Time (TAT) of dry blood spots and associated factors in Vihiga, Bungoma, Kakamega and Busia counties, in Kenya. METHOD: A mixed methods study using a) retrospectively collected data from Ministry of Health Laboratory registers, Early Infant Diagnosis (EID) database from 28 health facilities and b) 9 key informant interviews with laboratory in-charges were conducted. A total of 2,879 HIV exposed babies' data were abstracted from January 2012 to June 2013. RESULTS: The mean TAT from specimen collection and results received back at the facilities was 46.90 days, Vihiga county having the shortest mean duration at 33.7days and Kakamega county having the longest duration at 51.7days (p = 0.001). In addition, the mean transport time from specimen collection and receipt at Alupe Kenya Medical Research Institute (KEMRI) reference Laboratory was 16.50 days. Vihiga County had the shortest transport time at 13.01 days while Busia had the longest at 18.99 days (p = 0.001). Longer TAT was due to the batching of specimens at the peripheral health facilities and hubbing to the nearest referral hospitals. CONCLUSION: The TAT for DNA-PCR specimen was 46.90 days with Vihiga County having the shortest TAT due to lack of specimen batching and hubbing. RECOMMENDATION: Discourage specimen batching/hubbing and support point-of-care early infant diagnosis (EID) tests.


Subject(s)
HIV Infections , Polymerase Chain Reaction , Humans , Kenya/epidemiology , Infant , HIV Infections/diagnosis , HIV Infections/epidemiology , Polymerase Chain Reaction/methods , Female , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Retrospective Studies , DNA, Viral , Male , Time Factors
5.
J Med Virol ; 96(5): e29652, 2024 May.
Article in English | MEDLINE | ID: mdl-38727029

ABSTRACT

Human papillomavirus (HPV) genotyping is widely used, particularly in combination with high-risk (HR) HPV tests for cervical cancer screening. We developed a genotyping method using sequences of approximately 800 bp in the E6/E7 region obtained by PacBio single molecule real-time sequencing (SMRT) and evaluated its performance against MY09-11 L1 sequencing and after the APTIMA HPV genotyping assay. The levels of concordance of PacBio E6/E7 SMRT sequencing with MY09-11 L1 sequencing and APTIMA HPV genotyping were 100% and 90.8%, respectively. The sensitivity of PacBio E6/EA7 SMRT was slightly greater than that of L1 sequencing and, as expected, lower than that of HR-HPV tests. In the context of cervical cancer screening, PacBio E6/E7 SMRT is then best used after a positive HPV test. PacBio E6/E7 SMRT genotyping is an attractive alternative for HR and LR-HPV genotyping of clinical samples. PacBio SMRT sequencing provides unbiased genotyping and can detect multiple HPV infections and haplotypes within a genotype.


Subject(s)
Genotype , Genotyping Techniques , Papillomaviridae , Papillomavirus Infections , Humans , Papillomavirus Infections/virology , Papillomavirus Infections/diagnosis , Female , Genotyping Techniques/methods , Papillomaviridae/genetics , Papillomaviridae/classification , Papillomaviridae/isolation & purification , Sensitivity and Specificity , Uterine Cervical Neoplasms/virology , Uterine Cervical Neoplasms/diagnosis , Sequence Analysis, DNA/methods , Early Detection of Cancer/methods , Oncogene Proteins, Viral/genetics , DNA, Viral/genetics , High-Throughput Nucleotide Sequencing/methods
6.
J Med Virol ; 96(5): e29654, 2024 May.
Article in English | MEDLINE | ID: mdl-38727099

ABSTRACT

Human Herpesvirus 8 (HHV-8) has been classified by sequence analysis of open reading frame (ORF) K1, ORF K15, and variable sequence loci within the central constant region. The purpose of this study was to examine the molecular epidemiology of HHV-8 in an Irish population. This retrospective study included 30 patients who had HHV-8 DNA detected in plasma. Nested end-point PCR was used to characterise four regions of the HHV-8 genome, K1, T0.7 (K12), ORF 75, and K15. Sequencing data were obtained for 23 specimens from 19 patients. Phylogenetic analysis of ORF K1 demonstrated that subtypes A, B, C and F were present in 37%, 11%, 47% and 5%, respectively. For T0.7 and ORF 75, sequencing data were obtained for 12 patients. For T0.7, subtypes A/C, J, B, R and Q were present in 58%, 17%, 8%, 8%, and 8%, respectively. For ORF 75, subtypes A, B, C and D were present in 58%, 8%, 25%, and 8%, respectively. K15 sequences were determined for 13 patients. 69% had the P allele and 31% had the M allele. The data generated by this study demonstrate that a broad variety of HHV-8 subtypes are represented in patients exhibiting HHV-8-related disease in Ireland, a low prevalence country. The predominance of C and A K1 subtypes was as expected for a Western European population. The 31% prevalence for K15 subtype M was higher than expected for a Western European population. This may represent the changing and evolving epidemiology in Ireland due to altered migration patterns.


Subject(s)
DNA, Viral , Herpesviridae Infections , Herpesvirus 8, Human , Molecular Epidemiology , Phylogeny , Sequence Analysis, DNA , Humans , Ireland/epidemiology , Herpesviridae Infections/epidemiology , Herpesviridae Infections/virology , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/classification , Herpesvirus 8, Human/isolation & purification , Male , Female , Retrospective Studies , Middle Aged , Adult , DNA, Viral/genetics , Aged , Young Adult , Polymerase Chain Reaction , Genotype , Adolescent , Open Reading Frames , Aged, 80 and over , Child , Molecular Sequence Data
7.
Sci Rep ; 14(1): 10169, 2024 05 03.
Article in English | MEDLINE | ID: mdl-38702375

ABSTRACT

Bovine viral diarrhea virus (BVDV) is considered to be the most common agent of severe diarrhea in cattle worldwide, causing fever, diarrhea, ulcers, and abortion. Bovine herpesvirus 1 (BoHV-1) is also a major bovine respiratory disease agent that spreads worldwide and causes extensive damage to the livestock industry. Recombinase polymerase amplification (RPA) is a novel nucleic acid amplification method with the advantages of high efficiency, rapidity and sensitivity, which has been widely used in the diagnosis of infectious diseases. A dual RPA assay was developed for the simultaneous detection of BVDV and BoHV-1. The assay was completed at a constant temperature of 37 °C for 30 min. It was highly sensitive and had no cross-reactivity with other common bovine viruses. The detection rate of BVDV RPA in clinical samples (36.67%) was higher than that of PCR (33.33%), the detection rate of BoHV-1 RPA and PCR were equal. Therefore, the established dual RPA assay for BVDV and BoHV-1 could be a potential candidate for use as an immediate diagnostic.


Subject(s)
Diarrhea Viruses, Bovine Viral , Herpesvirus 1, Bovine , Nucleic Acid Amplification Techniques , Recombinases , Animals , Cattle , Herpesvirus 1, Bovine/genetics , Herpesvirus 1, Bovine/isolation & purification , Nucleic Acid Amplification Techniques/methods , Recombinases/metabolism , Diarrhea Viruses, Bovine Viral/genetics , Diarrhea Viruses, Bovine Viral/isolation & purification , Sensitivity and Specificity , Bovine Virus Diarrhea-Mucosal Disease/virology , Bovine Virus Diarrhea-Mucosal Disease/diagnosis , Herpesviridae Infections/veterinary , Herpesviridae Infections/virology , Herpesviridae Infections/diagnosis , DNA, Viral/genetics
8.
Viruses ; 16(5)2024 05 08.
Article in English | MEDLINE | ID: mdl-38793626

ABSTRACT

HBV infection is challenging to cure due to the persistence of viral covalently closed circular viral DNA (cccDNA). The dedicator of cytokinesis 11 (DOCK11) is recognized as a guanine nucleotide exchange factor (GEF) for CDC42 that has been reported to be required for HBV persistence. DOCK11 is expressed in both the cytoplasm and nucleus of human hepatocytes and is functionally associated with retrograde trafficking proteins Arf-GAP with GTPase domain, ankyrin repeat, and pleckstrin homology domain-containing protein 2 (AGAP2), and ADP-ribosylation factor 1 (ARF1), together with the HBV capsid, in the trans-Golgi network (TGN). This opens an alternative retrograde trafficking route for HBV from early endosomes (EEs) to the TGN and then to the endoplasmic reticulum (ER), thereby avoiding lysosomal degradation. DOCK11 also facilitates the association of cccDNA with H3K4me3 and RNA Pol II for activating cccDNA transcription. In addition, DOCK11 plays a crucial role in the host DNA repair system, being essential for cccDNA synthesis. This function can be inhibited by 10M-D42AN, a novel DOCK11-binding peptide, leading to the suppression of HBV replication both in vitro and in vivo. Treatment with a combination of 10M-D42AN and entecavir may represent a promising therapeutic strategy for patients with chronic hepatitis B (CHB). Consequently, DOCK11 may be seen as a potential candidate molecule in the development of molecularly targeted drugs against CHB.


Subject(s)
Guanine Nucleotide Exchange Factors , Hepatitis B virus , Hepatocytes , Humans , Hepatitis B virus/physiology , Hepatitis B virus/genetics , Guanine Nucleotide Exchange Factors/metabolism , Guanine Nucleotide Exchange Factors/genetics , Hepatocytes/virology , Hepatocytes/metabolism , Virus Internalization , Virus Replication , Hepatitis B/virology , Hepatitis B/metabolism , DNA, Viral/metabolism , DNA, Viral/genetics , Animals
9.
Viruses ; 16(5)2024 05 08.
Article in English | MEDLINE | ID: mdl-38793630

ABSTRACT

During viral infection, the innate immune system utilizes a variety of specific intracellular sensors to detect virus-derived nucleic acids and activate a series of cellular signaling cascades that produce type I IFNs and proinflammatory cytokines and chemokines. Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic double-stranded DNA virus that has been associated with a variety of human malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Infection with KSHV activates various DNA sensors, including cGAS, STING, IFI16, and DExD/H-box helicases. Activation of these DNA sensors induces the innate immune response to antagonize the virus. To counteract this, KSHV has developed countless strategies to evade or inhibit DNA sensing and facilitate its own infection. This review summarizes the major DNA-triggered sensing signaling pathways and details the current knowledge of DNA-sensing mechanisms involved in KSHV infection, as well as how KSHV evades antiviral signaling pathways to successfully establish latent infection and undergo lytic reactivation.


Subject(s)
DNA, Viral , Herpesvirus 8, Human , Immunity, Innate , Signal Transduction , Herpesvirus 8, Human/genetics , Herpesvirus 8, Human/physiology , Humans , DNA, Viral/metabolism , Herpesviridae Infections/virology , Herpesviridae Infections/metabolism , Sarcoma, Kaposi/virology , Nucleotidyltransferases/metabolism , Host-Pathogen Interactions , Animals , Membrane Proteins/metabolism , Nuclear Proteins , Phosphoproteins
10.
Virol J ; 21(1): 108, 2024 05 10.
Article in English | MEDLINE | ID: mdl-38730285

ABSTRACT

BACKGROUND: The immature and suppressed immune response makes transplanted children a special susceptible group to Parvovirus B19 (PVB19). However, the clinical features of transplanted children with PVB19 infection haven't been comprehensively described. METHODS: We searched the medical records of all the transplant recipients who attended the Children's Hospital of Fudan University from 1 Oct 2020 to 31 May 2023, and reviewed the medical literature for PVB19 infection cases among transplanted children. RESULTS: A total of 10 cases of PVB19 infection were identified in 201 transplanted children at our hospital, and the medical records of each of these cases were shown. Also, we retrieved 40 cases of PVB19 infection among transplanted children from the literature, thus summarizing a total of 50 unique cases of PVB19 infection. The median time to the first positive PVB19 DNA detection was 14 weeks post-transplantation. PVB19 IgM and IgG were detected in merely 26% and 24% of the children, respectively. The incidence of graft loss/dysfunction was as high as 36%. Hematopoietic stem cell transplant (HSCT) recipients showed higher PVB19 load, lower HGB level, greater platelet damage, lower PVB19 IgM/IgG positive rates, and more graft dysfunction than solid-organ transplant (SOT) recipients, indicating a more incompetent immune system. CONCLUSIONS: Compared with the published data of transplanted adults, transplanted children displayed distinct clinical features upon PVB19 infection, including lower PVB19 IgM/IgG positive rates, more graft dysfunction, and broader damage on hematopoietic cell lines, which was even more prominent in HSCT recipients, thus should be of greater concern.


Subject(s)
Antibodies, Viral , Hematopoietic Stem Cell Transplantation , Parvoviridae Infections , Parvovirus B19, Human , Humans , Parvovirus B19, Human/immunology , Parvovirus B19, Human/genetics , Child , Female , Male , Child, Preschool , Parvoviridae Infections/virology , Parvoviridae Infections/immunology , Hematopoietic Stem Cell Transplantation/adverse effects , Antibodies, Viral/blood , Infant , Adolescent , Immunoglobulin M/blood , Immunoglobulin G/blood , Transplant Recipients , DNA, Viral/blood , Viral Load , Organ Transplantation/adverse effects
11.
BMC Cancer ; 24(1): 578, 2024 May 11.
Article in English | MEDLINE | ID: mdl-38734620

ABSTRACT

OBJECTIVE: This study aims to develop a nomogram integrating inflammation (NLR), Prognostic Nutritional Index (PNI), and EBV DNA (tumor burden) to achieve personalized treatment and prediction for stage IVA NPC. Furthermore, it endeavors to pinpoint specific subgroups that may derive significant benefits from S-1 adjuvant chemotherapy. METHODS: A total of 834 patients diagnosed with stage IVA NPC were enrolled in this study and randomly allocated into training and validation cohorts. Multivariate Cox analyses were conducted to identify independent prognostic factors for constructing the nomogram. The predictive and clinical utility of the nomogram was assessed through measures including the AUC, calibration curve, DCA, and C-indexes. IPTW was employed to balance baseline characteristics across the population. Kaplan-Meier analysis and log-rank tests were utilized to evaluate the prognostic value. RESULTS: In our study, we examined the clinical features of 557 individuals from the training cohort and 277 from the validation cohort. The median follow-up period was 50.1 and 49.7 months, respectively. For the overall cohort, the median follow-up duration was 53.8 months. The training and validation sets showed 3-year OS rates of 87.7% and 82.5%, respectively. Meanwhile, the 3-year DMFS rates were 95.9% and 84.3%, respectively. We created a nomogram that combined PNI, NRI, and EBV DNA, resulting in high prediction accuracy. Risk stratification demonstrated substantial variations in DMFS and OS between the high and low risk groups. Patients in the high-risk group benefited significantly from the IC + CCRT + S-1 treatment. In contrast, IC + CCRT demonstrated non-inferior 3-year DMFS and OS compared to IC + CCRT + S-1 in the low-risk population, indicating the possibility of reducing treatment intensity. CONCLUSIONS: In conclusion, our nomogram integrating NLR, PNI, and EBV DNA offers precise prognostication for stage IVA NPC. S-1 adjuvant chemotherapy provides notable benefits for high-risk patients, while treatment intensity reduction may be feasible for low-risk individuals.


Subject(s)
Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms , Neoplasm Staging , Nomograms , Humans , Male , Female , Middle Aged , Nasopharyngeal Carcinoma/drug therapy , Nasopharyngeal Carcinoma/mortality , Nasopharyngeal Carcinoma/pathology , Chemotherapy, Adjuvant/methods , Prognosis , Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/mortality , Nasopharyngeal Neoplasms/pathology , Inflammation , Adult , Nutrition Assessment , Herpesvirus 4, Human/isolation & purification , Tegafur/therapeutic use , Tegafur/administration & dosage , DNA, Viral , Drug Combinations , Oxonic Acid/therapeutic use , Oxonic Acid/administration & dosage , Aged , Kaplan-Meier Estimate
12.
PeerJ ; 12: e17302, 2024.
Article in English | MEDLINE | ID: mdl-38737747

ABSTRACT

Background: Hepatitis B virus (HBV) infection poses a major public health problem worldwide. Bovine lactoferrin (bLf) is a natural product that can inhibit HBV, but the effect of iron saturation on its resistance to HBV is unknown. Aims: The purpose of this study is to investigate the impact of iron saturation of bLf against HBV. Methods: HepG2 cells were cultured in DMEM high glucose containing 10% inactivated fetal calf serum, at 37 °C, in 5% CO2. MTT method was used to detect the cytotoxicity of bLf to HepG2 cells. Apo-bLf and holo-bLf were prepared from bLf. Iron saturation of these proteins was determined by atomic absorption spectrophotometry. Non-cytotoxic concentrations of candidate proteins were used in anti-HBV tests. Fluorescent quantitative polymerase chain reaction was used to detect HBV-DNA. Results: The TC50 and TC0of bLf were 54.570 mg/ml and 1.997 mg/ml, respectively. The iron saturation of bLf, apo-bLf and holo-bLf were 10.29%, 8.42% and 85.32%, respectively. In this study, four non-cytotoxic concentrations of candidate proteins (1.5, 1.0, 0.5, and 0.1 mg/ml, respectively) were used to inhibit HBV in HepG2 cells. The results showed that 1.5 mg/ml bLf and 0.1 mg/ml holo-bLf effectively impaired the HBV-DNA amplification in HBV-infected HepG2 cells (P < 0.05). However, apo-bLf, and Fe3+ did not show the anti-HBV effects. Conclusion: A total of 1.5 mg/ml bLf and 0.1 mg/ml holo-bLf could inhibit HBV-DNA in HepG2 cells. Complete bLf structure, appropriate concentration and iron saturation of bLf are necessary conditions for anti-HBV effects.


Subject(s)
Antiviral Agents , Hepatitis B virus , Iron , Lactoferrin , Lactoferrin/pharmacology , Humans , Hep G2 Cells , Hepatitis B virus/drug effects , Cattle , Animals , Antiviral Agents/pharmacology , Iron/metabolism , DNA, Viral/drug effects
13.
Arch Virol ; 169(6): 119, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38753197

ABSTRACT

Porcine circovirus (PCV) has become a major pathogen, causing major economic losses in the global pig industry, and PCV type 2 (PCV2) and 3 (PCV3) are distributed worldwide. We designed specific primer and probe sequences targeting PCV2 Cap and PCV3 Rap and developed a multiplex crystal digital PCR (cdPCR) method after optimizing the primer concentration, probe concentration, and annealing temperature. The multiplex cdPCR assay permits precise and differential detection of PCV2 and PCV3, with a limit of detection of 1.39 × 101 and 1.27 × 101 copies/reaction, respectively, and no cross-reaction with other porcine viruses was observed. The intra-assay and interassay coefficients of variation (CVs) were less than 8.75%, indicating good repeatability and reproducibility. To evaluate the practical value of this assay, 40 tissue samples and 70 feed samples were tested for both PCV2 and PCV3 by cdPCR and quantitative PCR (qPCR). Using multiplex cdPCR, the rates of PCV2 infection, PCV3 infection, and coinfection were 28.45%, 1.72%, and 12.93%, respectively, and using multiplex qPCR, they were 25.00%, 0.86%, and 4.31%, respectively This highly specific and sensitive multiplex cdPCR thus allows accurate simultaneous detection of PCV2 and PCV3, and it is particularly well suited for applications that require the detection of small amounts of input nucleic acid or samples with intensive processing and complex matrices.


Subject(s)
Circoviridae Infections , Circovirus , Multiplex Polymerase Chain Reaction , Swine Diseases , Circovirus/genetics , Circovirus/isolation & purification , Circovirus/classification , Swine , Animals , Circoviridae Infections/veterinary , Circoviridae Infections/virology , Circoviridae Infections/diagnosis , Swine Diseases/virology , Swine Diseases/diagnosis , Multiplex Polymerase Chain Reaction/methods , Sensitivity and Specificity , Reproducibility of Results , DNA Primers/genetics , DNA, Viral/genetics
14.
Arch Virol ; 169(6): 120, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38753261

ABSTRACT

Gyroviruses are small single-stranded DNA (ssDNA) viruses that are largely associated with birds. Chicken anemia virus is the most extensively studied gyrovirus due to its disease impact on the poultry industry. However, we know much less about gyroviruses infecting other avian species. To investigate gyroviruses infecting waterfowl, we determined six complete genome sequences that fall into three gyrovirus groups, referred to as waterfowl gyrovirus 1 (n = 3), 2 (n = 2), and 3 (n = 1), in organs from hunter-harvested waterfowl from Arizona (USA). The waterfowl gyrovirus 1 variants were identified in multiple organs of a single American wigeon and represent a tentative new species. The waterfowl gyrovirus 2 variants were identified in the livers of two American wigeons and share >70% VP1 nucleotide sequence identity with gyrovirus 9, previously identified in the spleen of a Brazilian Pekin duck (MT318123) and a human fecal sample (KP742975). Waterfowl gyrovirus 3 was identified in a northern pintail spleen sample, and it shares >73% VP1 nucleotide sequence identity with two gyrovirus 13 sequences previously identified in Brazilian Pekin duck spleens (MT318125 and MT318127). These gyroviruses are the first to be identified in waterfowl in North America, as well as in American wigeons and northern pintails.


Subject(s)
Bird Diseases , Circoviridae Infections , Genome, Viral , Gyrovirus , Phylogeny , Animals , Arizona , Genome, Viral/genetics , Gyrovirus/genetics , Gyrovirus/classification , Gyrovirus/isolation & purification , Bird Diseases/virology , Circoviridae Infections/virology , Circoviridae Infections/veterinary , Anseriformes/virology , Ducks/virology , DNA, Viral/genetics
15.
Clin Lab ; 70(5)2024 May 01.
Article in English | MEDLINE | ID: mdl-38747904

ABSTRACT

BACKGROUND: Hepatitis B caused by hepatitis B virus (HBV) infection is a serious global public health issue. Currently, serological indicators serve as important markers for the diagnosis of hepatitis B. It has been found that HBV core-related antigen (HBcrAg) correlates well with intrahepatic cccDNA, intrahepatic HBV DNA, serum HBV DNA, and hepatitis B e antigen (HBeAg). To provide a more reliable basis for the diagnosis and treatment of hepatitis B, we explored the correlation between HBcrAg and conventional serologic testing indicators and disease staging. METHODS: Five hundred forty-two patient serum samples were collected at the First Affiliated Hospital of Soochow University from November 2021 to March 2022. The serum HBcrAg was measured by the magnetic particle chemiluminescence method in addition with other serum indicators. RESULTS: HBcrAg statistically correlated with HBV DNA level (r = 0.655, p < 0.001) and HBeAg level (r = 0.945, p < 0.001. The mean HBcrAg levels in the immune-tolerant and immune-clearance phases were significantly higher than those in the immunologic-control phase and the reactivation phase. This study demonstrated that serum HBcrAg positively correlated with serum HBV DNA and HBeAg. Even in cases where HBV DNA and HBeAg are negative, there is still a higher positivity rate of HBcrAg in hepatitis B patients. CONCLUSIONS: HBcrAg is a reliable serum marker to avoid underdiagnosis of occult HBV infection.


Subject(s)
Biomarkers , DNA, Viral , Hepatitis B Core Antigens , Hepatitis B e Antigens , Hepatitis B virus , Hepatitis B , Humans , Hepatitis B Core Antigens/blood , Hepatitis B Core Antigens/immunology , Male , Female , Hepatitis B/diagnosis , Hepatitis B/immunology , Hepatitis B/blood , Hepatitis B/virology , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/immunology , Hepatitis B virus/immunology , Hepatitis B virus/genetics , Adult , Biomarkers/blood , Middle Aged , DNA, Viral/blood , Young Adult , Aged , Adolescent
16.
Clin Lab ; 70(5)2024 May 01.
Article in English | MEDLINE | ID: mdl-38747912

ABSTRACT

BACKGROUND: The goal was to study the difference of virological, immunologic, and inflammatory indicators between Epstein-Barr associated infectious mononucleosis (EBV-IM) and EBV associated hemophagocytic lymphohistiocytosis (EBV-HLH) and to explore the evaluation indicators for monitoring the therapeutic efficacy of EBV-HLH. METHODS: Twenty children with EBV-IM (IM group) and 10 children with EBV-HLH (HLH group) were selected. Virology indicators were detected; the absolute count of lymphocyte, and lymphocyte subsets were detected; the levels of immunoglobulin and ferritin were assayed. RESULTS: Compared to the IM group, the HLH group showed a decrease in EBV-specific VCA-IgM antibody levels (U = 29.0, p = 0.006) and an increase in EBV-specific NA-IgG antibody levels (U = 17.0, p = 0.001), while there was no significant difference in EB-DNA loads (t = 0.417, p = 0.680). The counts of lymphocytes, and various lymphocyte subsets in the HLH group were lower than those in the IM group. Inflammatory markers in the HLH group were significantly higher than those in IM group. Dynamic monitoring of virological, immunological, and inflammatory indicators in HLH patients during treatment showed that EBV DNA gradually decreased in patients with good prognosis. Inflammatory indicators significantly decreased and returned to normal, lymphocyte count significantly increased and returned to normal during treatment. However, patients with poor prognosis showed rebound increase in EBV DNA and inflammatory indicators in the later stage of treatment, while lymphocyte count further decreased with the recurrence of the disease. CONCLUSIONS: Exhausted and damaged immune function in host by persistent stimulation of EB viral antigen is one of the main pathogeneses of EB-HLH. Lymphocyte count and serum ferritin level are effective indicators to monitor the therapeutic efficacy during the treatment to HLH.


Subject(s)
Epstein-Barr Virus Infections , Herpesvirus 4, Human , Infectious Mononucleosis , Lymphohistiocytosis, Hemophagocytic , Humans , Child , Male , Female , Child, Preschool , Herpesvirus 4, Human/immunology , Lymphohistiocytosis, Hemophagocytic/immunology , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/virology , Lymphohistiocytosis, Hemophagocytic/blood , Infectious Mononucleosis/immunology , Infectious Mononucleosis/blood , Infectious Mononucleosis/virology , Infectious Mononucleosis/diagnosis , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Epstein-Barr Virus Infections/blood , DNA, Viral/blood , Inflammation/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Viral Load , Ferritins/blood , Lymphocyte Count , Adolescent , Infant , Lymphocyte Subsets/immunology
17.
Methods Mol Biol ; 2807: 163-171, 2024.
Article in English | MEDLINE | ID: mdl-38743228

ABSTRACT

Mammalian cells have developed and optimized defense mechanisms to prevent or hamper viral infection. The early transcriptional silencing of incoming viral DNAs is one such antiviral strategy and seems to be of fundamental importance, since most cell types silence unintegrated retroviral DNAs. In this chapter, a method for chromatin immunoprecipitation of unintegrated DNA is described. This technique allows investigators to examine histone and co-factor interactions with unintegrated viral DNAs as well as to analyze histone modifications in general or in a kinetic fashion at various time points during viral infection.


Subject(s)
Chromatin Immunoprecipitation , Genome, Viral , Histones , Retroviridae , Histones/metabolism , Humans , Chromatin Immunoprecipitation/methods , Retroviridae/genetics , Viral Proteins/genetics , Viral Proteins/metabolism , Viral Proteins/immunology , Animals , DNA, Viral/genetics , Antibodies/immunology
18.
Zhonghua Gan Zang Bing Za Zhi ; 32(4): 295-299, 2024 Apr 20.
Article in Chinese | MEDLINE | ID: mdl-38733181

ABSTRACT

The ideal goal of hepatitis B treatment is to achieve a functional cure, and the persistent cccDNA in the liver is a barrier to functional cure. Currently, antiviral drugs represented by pegylated interferon-α and nucleos (t) ide analogues cannot eliminate cccDNA, which is difficult to achieve functional cure. With the deepening of the exploration of various mechanisms and drug targets, significant progress has been made in the research and development of several novel drugs targeting the hepatitis B virus's life cycle and immune system, offering hope for a functional cure. This article presents an overview of the new progress in clinical research on antiviral therapy for chronic hepatitis B based on the literature published in recent years and international conference materials.


Subject(s)
Antiviral Agents , Hepatitis B virus , Hepatitis B, Chronic , Antiviral Agents/therapeutic use , Antiviral Agents/pharmacology , Humans , Hepatitis B, Chronic/drug therapy , Hepatitis B virus/drug effects , Interferon-alpha/therapeutic use , Interferon-alpha/pharmacology , DNA, Viral
19.
Zhonghua Gan Zang Bing Za Zhi ; 32(4): 375-379, 2024 Apr 20.
Article in Chinese | MEDLINE | ID: mdl-38733195

ABSTRACT

Hepatitis B virus (HBV) DNA integration occurs during the reverse transcription process of HBV replication, which develops in the early stages of HBV infection and accompanies the entire disease course. The integration of HBV DNA is detrimental to the attainment of clinical cure goals and also raises the risk of developing liver cancer. Theoretically, nucleos(t)ide analogs can reduce the synthesis of new double-stranded linear DNA, but there is no clearance function for hepatocytes that have already integrated HBV. Therefore, patients with serum HBV DNA-negative conversions still have the risk of developing liver cancer. As an immunomodulatory drug, interferon can not only inhibit viral replication but also inhibit or even eliminate existing clonally amplified hepatocytes carrying integrated HBV DNA fragments. However, there are currently few studies on the effects of nucleos(t)ide analogues and interferon therapy on HBV DNA integration. Thus, large-scale clinical studies are urgently needed for further clarification.


Subject(s)
Antiviral Agents , DNA, Viral , Hepatitis B virus , Hepatitis B virus/drug effects , Hepatitis B virus/genetics , Humans , Antiviral Agents/therapeutic use , Antiviral Agents/pharmacology , Virus Integration , Hepatitis B/drug therapy , Hepatitis B/virology , Virus Replication/drug effects , Interferons/therapeutic use
20.
Zhonghua Gan Zang Bing Za Zhi ; 32(4): 325-331, 2024 Apr 20.
Article in Chinese | MEDLINE | ID: mdl-38733187

ABSTRACT

Objective: To analyze the hepatic tissue inflammatory activity and influencing factors in HBeAg-positive patients during normal alanine aminotransferase (ALT) and indeterminate phases so as to provide a basis for evaluating the disease condition. Methods: Patients with HBeAg-positive with normal ALT and HBV DNA levels below 2 × 10(7) IU/ml from January 2017 to December 2021 were selected as the study subjects. A histopathologic liver test was performed on these patients. Age, gender, time of HBV infection, liver function, HBsAg level, HBV DNA load, genotype, portal vein inner diameter, splenic vein inner diameter, splenic thickness, and others of the patients were collected. Significant influencing factors of inflammation were analyzed in patients using logistic regression analysis, and its effectiveness was evaluated using receiver operating characteristic (ROC) curves. Results: Of the 178 cases, there were 0 cases of inflammation in G0, 52 cases in G1, 101 cases in G2, 24 cases in G3, and one case in G4. 126 cases (70.8%) had inflammatory activity ≥ G2. Infection time (Z=-7.138, P<0.001), γ-glutamyltransferase (t =-2.940, P=0.004), aspartate aminotransferase (t =-2.749, P=0.007), ALT (t =-2.153, P=0.033), HBV DNA level (t =-4.771, P=0.010) and portal vein inner diameter (t =-4.771, P<0.001) between the ≥G2 group and < G2 group were statistically significantly different. A logistic regression analysis showed that significant inflammation in liver tissue was independently correlated with infection time [odds ratio (OR)=1.437, 95% confidence interval (CI): 1.267-1.630; P<0.001)] and portal vein inner diameter (OR=2.738, 95% CI: 1.641, 4.570; P<0.001). The area under the curve (AUROC), specificity, and sensitivity for infection time and portal vein inner diameter were 0.84, 0.71, 0.87, 0.72, 0.40, and 0.95, respectively. Conclusion: A considerable proportion of HBeAg-positive patients have inflammation grade ≥G2 during normal ALT and indeterminate phases, pointing to the need for antiviral therapy. Additionally, inflammatory activity has a close association with the time of infection and portal vein inner diameter.


Subject(s)
Alanine Transaminase , Hepatitis B e Antigens , Hepatitis B virus , Liver , Humans , Liver/pathology , Alanine Transaminase/blood , Hepatitis B e Antigens/blood , Inflammation , DNA, Viral , Male , Hepatitis B, Chronic/pathology , Female , Logistic Models , ROC Curve , Portal Vein , Hepatitis B , gamma-Glutamyltransferase/blood , Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...